Increasing awareness among patients, technological advancements in the sector of aesthetic treatment of pigmentation related conditions, and growing geriatric population have been pivotal in dictating the growth of the hypopigmentation disorders treatment market. Moreover, increasing incidences of disorders related to hypopigmentation, namely albinism, and vitiligo is anticipated to be the major driver of the global hypopigmentation disorders treatment market between 2019 and 2030.
Major Key Players of the Hypopigmentation Disorders Treatment Market are:
ALLERGAN, SkinCeuticals International, PIERRE FABRE GROUP, Episciences, RXi Pharmaceuticals, Obagi Cosmeceuticals, and Alvogen among others
Increasing Incidences of Vitiligo
According to the American Academy of Dermatology, vitiligo is considered to be among 24 skin diseases, which are widely prevalent among the population. Vitiligo is known to affect individuals from all ethnic background and genders equivalently. While, vitiligo can affect people from all ages, but the prevalence of the same is more prominent among individuals between the age 10 and 30 years. Moreover, in 2013, it was estimated that more than 150,000 Americans from all age groups underwent treatment for vitiligo. Rising incidences and prevalence of vitiligo is anticipated to further contribute to the growing demand of the global hypopigmentation disorders treatment market.
The Hypopigmentation Disorders Treatment Market is segmented on the basis of Treatment Type, Disease Indication, End Users and region.
Major Treatment Type of Hypopigmentation Disorders Treatment Market covered are:
- Topical Drugs
- Chemical Peels
- Laser Therapy, and Microdermabrasion
Major Disease Indication of Hypopigmentation Disorders Treatment Market covered are:
- Albinism
- Vitiligo
Major End Users of Hypopigmentation Disorders Treatment Market covered are:
- Dermatology Centers
- Aesthetic Clinics
- Hospitals
No comments:
Post a Comment